Related Experiment Video
Updated: Aug 18, 2025
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Modulation of the Microglial Nogo-A/NgR Signaling Pathway as a Therapeutic Target for Multiple Sclerosis
Danica Nheu1, Olivia Ellen1, Sining Ye1
1Department of Neuroscience, Central Clinical School, Monash University, Prahran, VIC 3004, Australia.
Abstract:
Current therapeutics targeting chronic phases of multiple sclerosis (MS) are considerably limited in reversing the neural damage resulting from repeated inflammation and demyelination insults in the multi-focal lesions. This inflammation is propagated by the activation of microglia, the endogenous immune cell aiding in the central nervous system homeostasis. Activated microglia may transition into polarized phenotypes; namely, the classically activated proinflammatory phenotype (previously categorized as M1) and the alternatively activated anti-inflammatory phenotype (previously, M2). These transitional microglial phenotypes are dynamic states, existing as a continuum. Shifting microglial polarization to an anti-inflammatory status may be a potential therapeutic strategy that can be harnessed to limit neuroinflammation and further neurodegeneration in MS. Our research has observed that the obstruction of signaling by inhibitory myelin proteins such as myelin-associated inhibitory factor, Nogo-A, with its receptor (NgR), can regulate microglial cell function and activity in pre-clinical animal studies. Our review explores the microglial role and polarization in MS pathology. Additionally, the potential therapeutics of targeting Nogo-A/NgR cellular mechanisms on microglia migration, polarization and phagocytosis for neurorepair in MS and other demyelination diseases will be discussed.
Insights
Targeting myelin proteins like Nogo-A/NgR may shift microglia to an anti-inflammatory state, potentially reversing neural damage in multiple sclerosis (MS) and other demyelination diseases.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Current multiple sclerosis (MS) therapies struggle to reverse neural damage caused by chronic inflammation and demyelination.
- Microglia, the central nervous system's immune cells, play a key role in MS pathology through their polarization into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes.
- Modulating microglial polarization towards an anti-inflammatory state presents a promising therapeutic avenue for MS.
Purpose of the Study:
- To explore the role of microglial polarization in multiple sclerosis (MS) pathogenesis.
- To investigate the potential of targeting myelin-associated inhibitory proteins, specifically Nogo-A and its receptor (NgR), as a therapeutic strategy for MS.
- To discuss the impact of Nogo-A/NgR signaling on microglial functions like migration, polarization, and phagocytosis for neurorepair.
Main Methods:
- Review of existing literature on microglial biology and polarization in MS.
- Analysis of pre-clinical animal studies investigating the effects of Nogo-A/NgR pathway modulation on microglial activity.
- Exploration of therapeutic strategies targeting the Nogo-A/NgR pathway for neurorepair in demyelinating diseases.
Main Results:
- Inhibiting Nogo-A/NgR signaling can influence microglial cell function and activity in pre-clinical models.
- The Nogo-A/NgR pathway is implicated in regulating microglial migration, polarization, and phagocytosis.
- Shifting microglial polarization to an anti-inflammatory phenotype is achievable through targeting this pathway.
Conclusions:
- Targeting the Nogo-A/NgR pathway offers a potential strategy to limit neuroinflammation and neurodegeneration in MS.
- Modulating microglial polarization via Nogo-A/NgR inhibition may promote neurorepair in MS and other demyelinating conditions.
- Further research into Nogo-A/NgR therapeutics could lead to novel treatments for chronic MS phases.
